Despite the success Gilead Sciences has experienced with the JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.

J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.

IFM Therapeutics subsidiary IFM Due and Novartis will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.

AstraZeneca’s experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage trial. During 2018, anifrolumab failed to meet the primary target in the final stage of another study.

AbbVie’s Rinvoq was approved by the FDA for treating adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

Gilead Sciences Inc. and Galapagos NV announced that the Marketing Authorization Application for filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis – was validated and is under evaluation by the European Medicines Agency.

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

LEO Pharma Inc announced the U.S. Food and Drug Administration expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. Additionally, the FDA approved Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension in the topical treatment of scalp and body plaque psoriasis in patients 12 years and older.

Four months after reporting success in two rheumatoid arthritis trials with developmental partner Galapagos NV, Gilead Sciences Inc. is strengthening that partnership with a 10-year global research and development collaboration worth more than $5 billion. Gilead is also increasing the company’s stake in Galapagos.

Gilead Sciences announced that a path forward was established to submit a New Drug Application in 2019 for the investigational oral, selective JAK1 inhibitor filgotinib as a rheumatoid arthritis treatment.